In clinical trials, it refers to summarized, anonymized information compiled from multiple patients, study sites, or trials rather than individual-level data.
Aggregate data combines raw data into population-level – indicating averages, totals, and percentages – to analyze trends, safety, and efficacy across large groups while ensuring patient confidentiality.
For example, instead of listing each patient’s adverse events, aggregate data provides the total counts of adverse events per treatment group. This approach provides a high-level view of a study’s outcome, making it easier to identify safety issues across multiple trials and protect patient privacy. Aggregate data is crucial for regulatory submissions (e.g., to EMA) and to determine if a drug is effective on a population level.
- OMOPHub. The Vocabulary stack for Healthcare Data Teams https://omophub.com
